# Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

> **NCT05857384** · PHASE1 · COMPLETED · sponsor: **Incannex Healthcare Ltd** · enrollment: 125 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** IHL42X
- **DRUG:** Acetazolamide 250 MG
- **DRUG:** Dronabinol 2.5 MG

## Key facts

- **NCT ID:** NCT05857384
- **Lead sponsor:** Incannex Healthcare Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-08
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857384, "Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05857384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*